You have 9 free searches left this month | for more free features.

Condition

Endometrial Cancer (1)

Metastatic Cancer (1)

Ovarian Cancer (1)

Recurrent Endometrial Cancer (1)

Recurrent Ovarian Cancer (1)

Small Cell Lung Cancer (1)

Overall Status

Terminated (1)

Unknown status (1)

Withdrawn (1)

Sign in for free

Phase

phase 1 (1)

phase 1/phase 2 (1)

phase 2 (1)

Sponsor

Gruppo Oncologico Italiano di Ricerca Clinica (1)

Immodulon Therapeutics Ltd (1)

Rutgers, The State University of New Jersey (1)

Collaborator

Clirest s.r.l. (1)

Istituto Toscano Tumori (1)

Mipharm S.p.A. (1)

National Cancer Institute (NCI) (1)

Rutgers Cancer Institute of New Jersey (1)

Temas srl (1)

Study Documents

Intervention Type

drug (3)

biological (1)

Funder Type

Other (2)

Industry (1)

Study Type

Interventional (3)

nabpaclitaxel

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Ovarian Cancer, Endometrial Cancer, Recurrent Ovarian Cancer Trial (BKM120, Nabpaclitaxel)

Withdrawn

Ovarian Cancer
+3 more

BKM120
Nabpaclitaxel

(no location specified)

Jul 27, 2022

Metastatic Cancer Trial in Lyon, Villejuif, London (IMM-101, Gemcitabine, Nabpaclitaxel)

Terminated

Metastatic Cancer

IMM-101
+11 more

Lyon, France
+3 more

Aug 8, 2018

Small Cell Lung Cancer Trial in Italy (Nabpaclitaxel)

Unknown status

Small Cell Lung Cancer

Nabpaclitaxel

Cona, Ferrara, Italy
+25 more

Jul 24, 2017